J&J Predicts Phase 1 Trials of COVID-19 Vaccine by September

Johnson & Johnson has chosen a lead COVID-19 vaccine candidate, Ad26 SARS-CoV-2, and has entered into a $1 billion partnership with HHS for vaccine research.

The company said it is establishing new U.S. vaccine manufacturing capacity and scaling up capacity in other  countries to provide over one billion doses.

J&J said it expects to begin phase 1 human trials of the vaccine no later than September 2020 and anticipates that the first batches of the vaccine could be available for emergency use in early 2021.